|
Gilead inks agreement to acquire EpiTherapeutics
June 2015
SHARING OPTIONS:
FOSTER CITY, Calif. & COPENHAGEN, Denmark—Gilead Sciences Inc. has established a definitive agreement with privately held EpiTherapeutics ApS by which it has acquired EpiTherapeutics for $65 million, subject to certain purchase price adjustments. EpiTherapeutics focuses
on the development of novel cancer drugs based on epigenetics, and brings with it a library of first-in-class, selective small-molecule inhibitors of
epigenetic regulation of gene transcription, particularly histone demethylases.
“Epigenetics is a promising
area of research and the EpiTherapeutics team is a recognized scientific leader in this field,” Dr. Norbert Bischofberger, Gilead’s executive
vice president of research and development and chief scientific officer, said in a statement. “This therapeutic class represents a strategic fit with
our existing research portfolio, including the potential for novel combination approaches. We look forward to working with colleagues from EpiTherapeutics to
advance these programs toward clinical development in diseases with significant unmet medical need.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|